Clinical Trials Logo

Gastric Atrophy clinical trials

View clinical trials related to Gastric Atrophy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01824953 Completed - Gastric Cancer Clinical Trials

Long-term Follow-up Prognosis of Atrophic Gastritis After 3 Years

Start date: January 2010
Phase: N/A
Study type: Observational [Patient Registry]

Serum pepsinogen (PG) levels are considered reliable markers for progression of atrophic gastritis with a stepwise reduction in the serum PG I level or PG I/II ratio. A combination of serum PG levels and Helicobacter pylori serology are used as a biomarker strategy for detection of individuals at increased risk of gastric neoplasm based on Correa's hypothesis. The investigators aimed to uncover whether this combination method could predict the risk of gastric neoplasms and the progression of chronic atrophic gastritis after 3 years. All the participants will be followed for an expected average of 3 years.